TIGIT and ovarian cancer: For instance, dual blockade of TIGIT and LAG-3 in ovarian cancer models overcame compensatory checkpoint upregulation, while a tri-specific PD-L1/TIGIT/LAG-3 antibody outperformed benchmark therapies in T-cell expansion and tumor suppression (Huang et al., 2017; Yang et al., 2023).